WuXi Biologics Begins Construction of New Microbial Manufacturing Site
WuXi Biologics, a prominent global player in Contract Research, Development, and Manufacturing, is embarking on an exciting new chapter by launching construction of a state-of-the-art microbial manufacturing site. This multi-faceted facility will boost commercial production capabilities in the vibrant pharmaceutical development hub of Chengdu.
Features of the New Manufacturing Site
The microbial manufacturing site is set to include a 15,000L fermenter, facilitating the annual production of between 80 and 110 drug substance (DS) batches, with the capacity to expand up to 60,000L in the future. This ambitious project aims to not only enhance productivity but also position WuXi Biologics at the forefront of the pharmaceutical manufacturing arena.
Production Capacity and Innovation
Home to China’s first dual-chamber lyophilization production line, the new site will also feature a vial filling line. Overall, it boasts a drug product (DP) manufacturing capacity that exceeds 10 million vials annually. This monumental enhancement in manufacturing capabilities underscores WuXi Biologics’ resolve to address the surging global demand for advanced biologic therapies.
Advanced Manufacturing Technologies
The cutting-edge facilities will utilize WuXi Biologics' innovative microbial expression platform, EffiXTM, designed for the efficient development and production of biologics. With a focus on attaining high yield and maintaining consistent quality, the platform targets titers surpassing 15 g/L for non-mAb recombinant proteins.
Environmental Considerations
WuXi Biologics is integrating advanced automated systems into the design to guarantee regulatory compliance and operational excellence while prioritizing energy conservation and sustainability. The organization’s commitment to environmentally responsible practices includes optimizing process development and implementing comprehensive carbon tracking methodologies to curtail its environmental footprint while adhering to high production standards.
Strategic Partnerships and Product Development
As part of its operational strategy, WuXi Biologics will utilize this newly constructed site to manufacture VISEN Pharmaceuticals' flagship commercial product, Lonapegsomatropin. This long-acting growth hormone aims to address pediatric growth hormone deficiency (PGHD). The collaboration with VISEN Pharmaceuticals highlights the increasing partnerships that WuXi Biologics is forming within the biotechnology sector, which bolster the company’s offerings and capabilities.
Additionally, WuXi Biologics has entered into a strategic alliance with Virogen Biotechnology, showcasing its adaptability in the biotech field and its commitment to meeting the rising needs for innovative biologic therapies.
Leadership Insights
Dr. Chris Chen, CEO of WuXi Biologics, expressed enthusiasm regarding the investment in the Chengdu microbial manufacturing site. He proclaimed that this site represents a powerful augmentation to their comprehensive range of microbial solutions. With the global market for microbial products thriving, the Chengdu facility is uniquely positioned to harness this opportunity effectively.
Dr. Chen emphasized the strategic partnerships with leading pharmaceutical companies that not only validate the facility’s impressive capabilities but denote an important step forward in WuXi Biologics' mission to accelerate the provision of innovative therapies worldwide.
Frequently Asked Questions
What is the purpose of the new microbial manufacturing site?
The site will enhance WuXi Biologics' production capabilities, allowing for the manufacture of biologics and addressing the growing global demand for innovative therapies.
What technologies will be utilized at the new site?
The facility will incorporate advanced technologies, including WuXi Biologics' EffiXTM microbial expression platform, which focuses on high yield and stability.
How does WuXi Biologics prioritize sustainability?
WuXi Biologics is focusing on energy conservation and implementing environmentally conscious practices, including carbon tracking mechanisms to minimize their ecological impact.
What products will be manufactured at the new site?
The first commercial product will be Lonapegsomatropin, a long-acting growth hormone for pediatric growth hormone deficiency.
How does this site impact WuXi Biologics' market position?
This facility is expected to significantly strengthen WuXi Biologics’ manufacturing capabilities and help meet the increasing demand for advanced biologic therapies on a global scale.
